Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono

doi:10.1200/JCO.2007.15.9749

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

Gerhardt Attard, Alison H M Reid, Timothy A Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S Cooper, Stan B Kaye, David Dearnaley, Gloria Lee, Johann S de Bono

Research output: Contribution to journal › Article › peer-review

813 Citations (Scopus)

Abstract

Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.

Original language	English
Pages (from-to)	4563-71
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	26
Issue number	28
DOIs	https://doi.org/10.1200/JCO.2007.15.9749
Publication status	Published - 1 Oct 2008

Keywords

Adenocarcinoma
Administration, Oral
Aged
Aged, 80 and over
Androstenols
Castration
Disease Progression
Humans
Male
Middle Aged
Neoplasms, Hormone-Dependent
Prospective Studies
Prostatic Neoplasms
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2007.15.9749

Cite this

Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., Clark, J., Cooper, C. S., Kaye, S. B., Dearnaley, D., Lee, G., & de Bono, J. S. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology, 26(28), 4563-71. https://doi.org/10.1200/JCO.2007.15.9749

@article{c2d959e48be541e5ba9481346a08fe67,

title = "Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven",

abstract = "Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.",

keywords = "Adenocarcinoma, Administration, Oral, Aged, Aged, 80 and over, Androstenols, Castration, Disease Progression, Humans, Male, Middle Aged, Neoplasms, Hormone-Dependent, Prospective Studies, Prostatic Neoplasms, Treatment Outcome",

author = "Gerhardt Attard and Reid, {Alison H M} and Yap, {Timothy A} and Florence Raynaud and Mitch Dowsett and Sarah Settatree and Mary Barrett and Christopher Parker and Vanessa Martins and Elizabeth Folkerd and Jeremy Clark and Cooper, {Colin S} and Kaye, {Stan B} and David Dearnaley and Gloria Lee and {de Bono}, {Johann S}",

year = "2008",

month = oct,

day = "1",

doi = "10.1200/JCO.2007.15.9749",

language = "English",

volume = "26",

pages = "4563--71",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "28",

}

Attard, G, Reid, AHM, Yap, TA, Raynaud, F, Dowsett, M, Settatree, S, Barrett, M, Parker, C, Martins, V, Folkerd, E, Clark, J , Cooper, CS, Kaye, SB, Dearnaley, D, Lee, G & de Bono, JS 2008, 'Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven', Journal of Clinical Oncology, vol. 26, no. 28, pp. 4563-71. https://doi.org/10.1200/JCO.2007.15.9749

TY - JOUR

T1 - Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

AU - Attard, Gerhardt

AU - Reid, Alison H M

AU - Yap, Timothy A

AU - Raynaud, Florence

AU - Dowsett, Mitch

AU - Settatree, Sarah

AU - Barrett, Mary

AU - Parker, Christopher

AU - Martins, Vanessa

AU - Folkerd, Elizabeth

AU - Clark, Jeremy

AU - Cooper, Colin S

AU - Kaye, Stan B

AU - Dearnaley, David

AU - Lee, Gloria

AU - de Bono, Johann S

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.

AB - Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.

KW - Adenocarcinoma

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Androstenols

KW - Castration

KW - Disease Progression

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasms, Hormone-Dependent

KW - Prospective Studies

KW - Prostatic Neoplasms

KW - Treatment Outcome

U2 - 10.1200/JCO.2007.15.9749

DO - 10.1200/JCO.2007.15.9749

M3 - Article

C2 - 18645193

SN - 1527-7755

VL - 26

SP - 4563

EP - 4571

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 28

ER -